Miguel Martin, Patrick Neven and Joyce O'Shaughnessy
Jan 10, 2025, 19:16
Outlook for the HR+/HER2- MBC treatment landscape in 2025 and beyond – SPCC
SPCC shared on LinkedIn:
“Mark your calendars for this live webinar!
Date: 29 January 2025, 18:00 CET
Main topics:
∙ Review of the latest HR+ HER2- MBC data and description of the current and future treatment landscape
∙ Biomarker testing
∙ Biomarker vs non-biomarker driven treatment choices
∙ Optimal sequencing the current & future dependant on clinical characteristic (which?)
Discussant: Miguel Martin, ES
Experts: Patrick Neven, BE; Joyce O’Shaughnessy, US
Register now (free of charge).
This webinar is supported by an unrestricted educational grant from Eli Lilly.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 12, 2025, 18:47
Feb 12, 2025, 18:35
Feb 12, 2025, 18:21
Feb 12, 2025, 18:15
Feb 12, 2025, 18:03
Feb 12, 2025, 17:33
Feb 12, 2025, 17:28
Feb 12, 2025, 17:17
Feb 12, 2025, 16:51
Feb 12, 2025, 16:49